However, CD8+ T cell depletion before tumor implantation appeared to be a more effective strategy to reverse therapeutic efficacy compared with post-tumor implantation, suggesting that the timing of depletion was relevant to the therapeutic outcome. This evidence concerns the gene CD8A and neoplasm.